查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835585

MRI導引神經外科消融市場（按類型、技術、應用和最終用戶）—全球預測2025-2032

MRI Guided Neurosurgical Ablation Market by Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，MRI 引導的神經外科消融市場將成長至 60.2 億美元，複合年成長率為 4.99%。

主要市場統計數據
基準年2024年 40.7億美元
預計2025年 42.8億美元
預測年份：2032年 60.2億美元
複合年成長率（%） 4.99%

綜合概述成像精度和能量傳輸的創新如何重新定義神經外科消融的實踐模式和臨床決策

MRI引導下的神經外科消融術是影像精度、熱能和機械能傳輸以及微創技術的關鍵融合，正在重新定義顱內疾病的臨床治療路徑。即時成像、能量調製和儀器微型化的進步使臨床醫生能夠以毫米級精度進行靶向消融，同時最大限度地減少附帶組織損傷。因此，患者選擇標準、手術全期工作流程和跨學科協作模式正在不斷發展，以獲得諸如降低手術併發症發生率和加快患者康復等臨床益處。

這項臨床前景由涵蓋多種適應症的不斷擴展的依證塑造，並因器械人體工學、手術規劃軟體和術中監測的不斷改進而進一步增強。這些發展支持從開放性切除術向影像引導的經皮和經顱介入治療的轉變，從而提高安全性和有效性。同時，更廣泛的醫療環境——基於價值的採購、有限的資本預算以及對長期療效的更嚴格審查——正在推動醫療機構採用可重複且能證明對患者有益的技術。

本引言將重點放在區分競爭治療方法的技術屬性、決定採用的臨床重點以及影響採購的機構動態，從而為後續分析奠定基礎。隨後的總結將重點放在技術、臨床和經濟因素如何影響外科團隊、醫院系統和研究機構的決策。

影像、能量傳輸、機器人和人工智慧領域的創新如何重塑臨床路徑並加速微創神經外科切除術的採用

過去五年，MRI引導神經外科消融的技術基礎設施和臨床模式都發生了革命性的變化。高解析度術中MRI和改進的測溫技術使能量輸送系統能夠以前所未有的精確度運行，改變了外科醫生計算胼胝體病變風險和益處的方式。同時，聚焦能量治療方法和雷射系統的成熟為先前被認為無法手術或開放性切除高風險的患者打開了新的治療窗口。

同時，設備、軟體和數位健康的融合正在加速。先進的治療計畫平台融合了機器學習輔助的分割和預測性熱建模，從而實現病例模擬和個人化給藥策略，從而減少術中不確定性。機器人引導和導航系統的整合正在標準化手術軌跡和植入定位，以提高不同外科醫生和機構之間的可重複性。這些技術協同作用與簡化圍手術全期工作流程的程序創新相輔相成，從而提高了吞吐量，並實現了門診或短期住院治療的可能性。

臨床上，向微創消融的轉變改變了轉診模式和多學科協作。神經外科醫生、神經腫瘤科醫生、疼痛專家和功能神經外科醫生擴大共同管理候選患者，促進方案化評估和共用決策。付款方和機構對比較結果的興趣也日益濃厚，這導致他們更加重視註冊登記、上市後監測和前瞻性證據的產生。總而言之，這些轉變正在重新定義MRI引導消融的價值提案，並凸顯了整合策略的重要性。

評估 2025 年美國關稅對整個神經外科消融生態系統的設備採購、採購週期和服務模式的運作和策略影響

美國將於2025年加徵累積關稅，為從事MRI導引神經外科消融術的製造商、經銷商和醫療保健提供者創造了新的商業環境。關稅主導的成本壓力已影響到進口組件和專用零件，例如雷射模組、精密光學元件和高規格電子產品，而這些零件對於消融平台的性能和可靠性至關重要。面對不斷上升的投入成本，製造商正在評估籌資策略、重組供應商契約，在某些情況下，甚至加快本地化生產或尋找合格的替代組件供應商，以保持相當的設備性能。

醫院和門診中心的採購週期應對了更嚴格的資本配置，對整體擁有成本和服務合約的審查也更加嚴格。在資本採購談判中，醫療保健機構優先考慮可預測的維護成本和耗材的批量定價，以緩解關稅帶來的波動。同時，一些供應商將其商業模式轉向與績效掛鉤的服務合約和延長保固期，以保持競爭優勢並應對預算限制。

由於跨境貨物需要遵循新的海關程序和文件要求，監管和物流時間也受到了影響。臨床試驗申辦者和研究機構的設備交貨前置作業時間延長，迫使其調整入組時間表和臨床試驗硬體緊急時應對計畫。投入成本上升、採購週期延長以及商業條款變化的綜合影響，促使企業轉向戰略聯盟、本地化製造外包，並追求模組化設備架構，以減少對關稅敏感部件的依賴。這些調整正在塑造供應商的競爭力和組織在當前關稅範圍內的採購行為。

詳細的細分分析揭示了產品類型、核心技術、臨床適應症和最終用戶偏好如何決定採用動態和策略性產品定位

細分分析揭示了不同設備類型、技術、應用和最終用戶設定之間細微的採用和臨床一致性，有助於制定差異化的產品和市場策略。按類型，本文研究了聚焦超音波、雷射消熔和射頻消融術。聚焦超音波亞型分為高強度和低強度兩種模式；雷射消熔進一步分為二極體和光纖雷射技術；射頻消融術射頻消融術則分為雙極和單極兩種配置。每種類型都具有獨特的技術能力和臨床權衡，這會影響其對特定病變特徵和解剖限制的適用性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合機器學習演算法以提高 MRI 引導消融的準確性並減少附帶組織損傷
  • 推出高場術中 MRI 套件，用於神經外科消融手術期間的高級即時成像
  • 引進機器人 MRI 導引導管導航系統，提升腦腫瘤消融的標靶精度
  • 開發雲端基礎的分析平台，用於匯總術後熱感圖和患者結果數據
  • 實施針對特定患者的 3D 列印腦部模型，用於雷射間質熱療消融術前規劃

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. MRI導引神經外科消融市場（按類型）

  • 聚焦超音波
    • 高強度
    • 低強度
  • 雷射消熔
    • 二極體雷射
    • 光纖雷射
  • 射頻消融
    • 雙極
    • 單極

9. MRI導引神經外科消融市場（依技術）

  • 高強度聚焦超音波（HIFU）
  • 雷射間質熱療（LITT）

第 10 章 MRI 導引神經外科消融市場（按應用）

  • 腦腫瘤
    • 神經膠母細胞瘤
    • 腦膜瘤
    • 轉移性腫瘤
  • 慢性疼痛
    • 坐骨神經痛
    • 三叉神經痛
  • 癲癇
    • 局部癲癇
    • 顳葉癲癇
  • 運動障礙
    • 肌張力不全症
    • 自發性震顫
    • 帕金森氏症

第 11 章。 MRI 導引神經外科消融市場（按最終用戶）

  • 門診手術中心
  • 醫院
  • 研究機構

12. MRI導引神經外科消融市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章。 MRI 導引神經外科消融市場（按組）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. MRI導引神經外科消融市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Monteris Medical Corporation
    • INSIGHTEC Ltd
    • ClearPoint Neuro, Inc.
    • Siemens Healthineers AG
    • SternMed GmbH
    • Cook Group Incorporated
    • HCA International Limited
    • Ginger Healthcare Private Ltd.
    • Brown Neurosurgery
Product Code: MRR-036C5CF3A877

The MRI Guided Neurosurgical Ablation Market is projected to grow by USD 6.02 billion at a CAGR of 4.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.07 billion
Estimated Year [2025] USD 4.28 billion
Forecast Year [2032] USD 6.02 billion
CAGR (%) 4.99%

An integrated overview of how imaging precision and energy delivery innovations are redefining neurosurgical ablation practice patterns and clinical decision making

MRI guided neurosurgical ablation represents a pivotal convergence of imaging precision, thermal and mechanical energy delivery, and minimally invasive procedural techniques that are redefining clinical pathways for intracranial disease. Advances in real-time imaging, energy modulation, and instrument miniaturization now allow clinicians to perform targeted ablations with millimeter accuracy while minimizing collateral tissue injury. As a result, patient selection criteria, perioperative workflows, and interdepartmental collaboration models are evolving to capture the clinical benefits of reduced operative morbidity and faster recovery.

The clinical landscape is shaped by an expanding evidence base across multiple indications, augmented by iterative improvements in device ergonomics, procedural planning software, and intraoperative monitoring. These developments support a transition from open resections toward percutaneous and transcranial interventions that leverage imaging guidance to enhance safety and efficacy. Concurrently, the broader healthcare environment-characterized by value-based purchasing, constrained capital budgets, and intensified scrutiny of long-term outcomes-drives providers to adopt technologies that demonstrate reproducible, demonstrable patient benefit.

This introductory overview frames the remaining analysis by highlighting the technical attributes that differentiate competing modalities, the clinical priorities defining adoption, and the institutional dynamics that influence procurement. The synthesis that follows emphasizes how converging technological, clinical, and economic forces are shaping decision-making across surgical teams, hospital systems, and research institutions.

How converging innovations in imaging, energy delivery, robotics, and AI are reshaping clinical pathways and accelerating minimally invasive neurosurgical ablation adoption

The past five years have seen transformative shifts in both the technological underpinnings and the clinical framing of MRI guided neurosurgical ablation. High-resolution intraoperative MRI and improved thermometry methods have enabled energy delivery systems to operate with unprecedented precision, altering how surgeons weigh the risk-benefit calculus for lesions in eloquent brain regions. Simultaneously, the maturation of focused energy modalities and laser systems has opened new treatment windows for patients previously considered inoperable or high-risk for open resection.

Concurrently, convergence across device, software, and digital health domains has accelerated. Advanced treatment planning platforms now incorporate machine learning-assisted segmentation and predictive thermal modeling, enabling case simulation and personalized dosing strategies that reduce intraoperative uncertainty. Integration of robotic guidance and navigation systems has standardized trajectories and implant positioning, improving reproducibility across operators and sites. These technological synergies are complemented by procedural innovations that streamline perioperative workflows, enabling greater throughput and the potential for ambulatory or short-stay pathways.

Clinically, the shift toward minimally invasive ablation has changed referral patterns and multidisciplinary collaboration. Neurosurgeons, neuro-oncologists, pain specialists, and functional neurosurgeons increasingly co-manage candidates, promoting protocolized evaluation and shared decision-making. Payer and institutional attention to comparative outcomes is rising, prompting stronger emphasis on registries, post-market surveillance, and prospective evidence generation. Taken together, these shifts are redefining the value proposition of MRI guided ablation and elevating the importance of integrated clinical, regulatory, and commercial strategies.

Assessment of the operational and strategic effects that the 2025 United States tariffs have imposed on device sourcing, procurement cycles, and service models across the neurosurgical ablation ecosystem

The imposition of cumulative tariffs in the United States in 2025 introduced new operating conditions for manufacturers, distributors, and healthcare providers engaged in MRI guided neurosurgical ablation. Tariff-driven cost pressure has affected imported subassemblies and specialty components-such as laser modules, precision optics, and high-specification electronics-that are central to the performance and reliability of ablation platforms. Manufacturers faced with increased input costs have evaluated sourcing strategies, reconfigured supplier contracts, and in some cases accelerated efforts to localize production or qualify alternative component suppliers to preserve parity in device performance.

Procurement cycles at hospitals and ambulatory centers responded to tighter capital allocation by intensifying scrutiny of total cost of ownership and service agreements. Institutions negotiating capital purchases prioritized predictable maintenance expenses and bundled consumable pricing to mitigate the variability introduced by tariffs. In parallel, some suppliers shifted commercial models toward outcome-linked service contracts and extended warranties to maintain competitive advantage and accommodate budgetary constraints.

Regulatory and logistics timelines were also affected as cross-border shipments navigated new customs processes and documentation requirements. For clinical trial sponsors and research institutes, extended lead times for device delivery necessitated adjustments to enrollment schedules and contingency planning for trial hardware. The combined effect of higher input costs, longer procurement timelines, and altered commercial terms has incentivized strategic collaborations, contract manufacturing localization, and the pursuit of modular device architectures that reduce dependence on tariff-sensitive components. These adaptations are shaping supplier competitiveness and institutional procurement behavior beyond the immediate tariff window.

Deep segmentation analysis revealing how device types, core technologies, clinical indications, and end-user settings determine adoption dynamics and strategic product positioning

Segmentation analysis reveals nuanced adoption and clinical alignment across device types, technologies, applications, and end-user settings, informing differentiated product and market strategies. Based on Type, the landscape is studied across Focused Ultrasound, Laser Ablation, and Radiofrequency Ablation; the Focused Ultrasound subtypes divide into High Intensity and Low Intensity modalities; Laser Ablation further differentiates into Diode Laser and Fiber Laser technologies; and Radiofrequency Ablation is examined in Bipolar and Monopolar configurations. Each type presents distinct technical capabilities and clinical trade-offs that influence suitability for specific lesion characteristics and anatomical constraints.

Based on Technology, the market analysis contrasts High-Intensity Focused Ultrasound (HIFU) with Laser Interstitial Thermal Therapy (LITT), emphasizing differences in energy deposition dynamics, thermal spread, and compatibility with concurrent MRI thermometry. The technical distinctions between HIFU and LITT translate into divergent procedural workflows, patient preparation requirements, and infrastructure implications, thereby affecting institutional adoption patterns.

Based on Application, the clinical segmentation covers Brain Tumors, Chronic Pain, Epilepsy, and Movement Disorders; within Brain Tumors, the focus includes Glioblastoma, Meningioma, and Metastatic Tumors; Chronic Pain is examined with attention to Sciatica and Trigeminal Neuralgia; Epilepsy analysis separates Focal Epilepsy and Temporal Lobe Epilepsy; and Movement Disorders are considered across Dystonia, Essential Tremor, and Parkinson's Disease. These application-level distinctions are critical because therapeutic intent, required precision, acceptable thermal margins, and outcome metrics differ substantially between oncologic and functional indications.

Based on End User, adoption dynamics vary across Ambulatory Surgical Centers, Hospitals, and Research Institutes, each of which demands tailored service models and capital strategies. Hospitals tend to prioritize robustness, multi-disciplinary applicability, and comprehensive service coverage, whereas ambulatory centers emphasize throughput efficiency and simplified logistical requirements, and research institutes prioritize flexibility for protocol testing and instrumentation modifications. Together, these segmentation insights indicate that successful market players align product design, clinical evidence generation, and commercial engagement to the specific technical and institutional requirements of the segment they target.

Comparative regional evaluation showing how regulatory, reimbursement, clinical infrastructure, and localization strategies drive differentiated adoption patterns across global markets

Regional dynamics for MRI guided neurosurgical ablation reveal distinct opportunity spaces and operational constraints shaped by regulatory regimes, reimbursement environments, clinical infrastructure, and research investment. In the Americas, centers of excellence concentrated in tertiary hospitals and research networks are early adopters of image-guided ablation technologies, supported by active clinical trial activity and an emphasis on comparative effectiveness studies. Payment structures and regional variations in capital allocation influence the pace of diffusion, while strong clinical advocacy and surgeon-led initiatives drive referrals for complex indications.

In Europe, Middle East & Africa, the landscape is heterogeneous; Western European markets show mature regulatory frameworks and established specialist centers that integrate ablation into multidisciplinary care pathways, whereas emerging markets within the region experience uneven access to imaging infrastructure and variable reimbursement policies. Consequently, manufacturers and clinical partners often pursue phased introductions, leveraging clinical partnerships and outcomes data to expand utilization. Investment in training and clinician networks is particularly important to overcome procedural learning curves and standardize care pathways across geographically dispersed institutions.

In Asia-Pacific, rapid infrastructure expansion, rising research investment, and an increasing focus on minimally invasive interventions create fertile ground for adoption, but market entry strategies must account for diverse regulatory requirements, localized procurement preferences, and differing payer expectations. Regional manufacturing and service localization strategies can accelerate acceptance, especially where tariff or logistics considerations affect component availability. Across all regions, collaborative trials, local key opinion leader engagement, and tailored reimbursement strategies materially influence the rate at which new technologies become integrated into routine practice.

How industry participants are using clinical evidence, software ecosystems, strategic partnerships, and resilient supply chains to establish sustainable competitive advantage

Competitive behavior among companies operating in the MRI guided neurosurgical ablation landscape is characterized by a focus on clinical differentiation, technology integration, and service models that prioritize total procedural value. Leading firms invest heavily in clinical evidence programs that demonstrate procedural safety, functional outcomes, and quality-of-life improvements for selected indications, recognizing that robust data is a primary determinant of hospital procurement decisions and payer support. Beyond evidence generation, companies concentrate on strengthening their software ecosystems-treatment planning, thermometry visualization, and outcome tracking-to create high switching costs and embed their platforms within clinical workflows.

Strategic partnerships with imaging and navigation vendors, academic centers, and specialized service providers have become common as companies seek to de-risk development and accelerate clinical adoption. Business models increasingly combine capital equipment sales with recurring revenue streams from disposables, software subscriptions, and extended service agreements. Attention to post-market surveillance and registry participation underscores a commitment to continuous safety monitoring and clinical improvement.

From an operational perspective, firms are optimizing supply chains and manufacturing footprints to mitigate geopolitical and tariff-related risk, as well as investing in scalable training programs to shorten the learning curve for new adopters. Competitive differentiation also arises from approaches to device modularity and interoperability, enabling integration into heterogeneous IT and imaging environments. Collectively, these company-level strategies indicate that long-term competitive advantage will accrue to organizations that align clinical value, operational resilience, and partner-enabled ecosystems.

Practical strategic moves for manufacturers and providers to accelerate adoption through evidence generation, platform differentiation, resilient supply chains, and tailored commercial models

Industry leaders should prioritize a coordinated set of tactical and strategic actions to capture clinical and commercial value as neurosurgical ablation technologies evolve. First, invest in indication-specific evidence generation that aligns clinical endpoints with payer and hospital decision criteria; prospective registries and randomized or comparative effectiveness studies will materially strengthen the value proposition for surgical teams and procurement committees. Second, build integrated digital tools for treatment planning, intraoperative monitoring, and outcomes tracking to enhance clinician productivity and create platform differentiation that extends beyond the hardware purchase.

Third, consider supply chain diversification and localized manufacturing partnerships to reduce exposure to tariff volatility and logistics disruptions; modular product architectures and qualified secondary suppliers for critical components can shorten lead times and stabilize service commitments. Fourth, tailor commercial models to end-user economics: offer financing, bundled service agreements, and outcome-linked pricing alternatives to address the capital constraints and reimbursement complexities of hospitals and ambulatory centers. Fifth, invest in comprehensive training and proctoring programs-delivered through a mix of in-person and virtual simulation-to accelerate adoption while protecting patient safety.

Finally, engage early with payers and health technology assessment bodies to align evidence generation with reimbursement needs, and pursue strategic clinical partnerships with academic centers to catalyze broader clinical acceptance. Executed together, these actions will position companies and provider organizations to translate technological promise into sustainable clinical adoption and institutional value.

Transparent multi-method research approach combining clinical expert interviews, device technical assessment, regulatory review, and supply chain analysis to validate insights and recommendations

The research underpinning this executive summary synthesizes qualitative and quantitative inputs derived from a structured blend of primary and secondary investigation techniques designed for triangulation and validation. Primary research included in-depth interviews with clinical experts across neurosurgery, neuro-oncology, pain management, and functional neurosurgery, as well as discussions with procurement leaders, clinical engineers, and research institute directors to capture practical deployment considerations and procurement behavior. Manufacturer interviews and targeted supplier consultations provided insight into technology roadmaps, manufacturing constraints, and service model evolution.

Secondary inputs comprised peer-reviewed clinical literature, regulatory guidance documents, procedural standards, and trial registries to assemble a comprehensive picture of safety, efficacy, and procedural protocols. Technical assessment incorporated device specifications, imaging integration requirements, and interoperability considerations derived from product documentation and engineering analyses. Supply chain and tariff impact analysis relied on customs regimes, import classifications, and publicly available trade policy summaries to evaluate potential operational effects.

Data synthesis employed iterative validation steps, reconciling divergent viewpoints through follow-up interviews and cross-referencing technical claims against clinical outcomes evidence. The methodology prioritized transparency in assumptions, careful separation of observed facts from expert opinion, and clear documentation of data sources to support reproducibility and to inform subsequent deep-dive investigations customized for specific strategic questions.

A concise synthesis of the strategic imperatives and collaborative priorities required to translate MRI guided ablation innovations into sustained clinical and commercial impact

MRI guided neurosurgical ablation stands at the intersection of rapid technological progress and evolving clinical practice, offering meaningful potential to improve patient outcomes while introducing new operational and commercial complexities. The collective trends-advances in imaging and thermometry, software-enabled planning, and shifting clinical pathways-signal a durable movement toward less invasive intracranial interventions that demand coordinated strategies from device manufacturers, healthcare providers, and policy stakeholders. Realizing the promise of these technologies requires investment in robust clinical evidence, adaptable commercial models, and resilient operational practices that can withstand geopolitical and supply chain variability.

Looking ahead, the ability of organizations to integrate clinical insights with pragmatic service offerings will determine adoption trajectories across applications and regions. Collaboration among device makers, imaging partners, clinician networks, and payers will be essential to create standardized pathways, accelerate training, and align reimbursement with demonstrated outcomes. As stakeholders navigate regulatory nuances, procurement constraints, and evolving clinical expectations, those that adopt a patient-centered, evidence-driven approach will be best positioned to convert technological capability into measurable improvements in care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of machine learning algorithms to enhance MRI guided ablation precision and reduce collateral tissue damage
  • 5.2. Deployment of high-field intraoperative MRI suites for advanced real-time imaging during neurosurgical ablation procedures
  • 5.3. Adoption of robot-assisted MRI guided catheter navigation systems for improved targeting accuracy in brain tumor ablation
  • 5.4. Development of cloud-based analytics platforms for aggregating postoperative thermal mapping and patient outcome data
  • 5.5. Implementation of patient-specific 3D printed brain phantoms for preoperative planning of laser interstitial thermal therapy ablation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Guided Neurosurgical Ablation Market, by Type

  • 8.1. Focused Ultrasound
    • 8.1.1. High Intensity
    • 8.1.2. Low Intensity
  • 8.2. Laser Ablation
    • 8.2.1. Diode Laser
    • 8.2.2. Fiber Laser
  • 8.3. Radiofrequency Ablation
    • 8.3.1. Bipolar
    • 8.3.2. Monopolar

9. MRI Guided Neurosurgical Ablation Market, by Technology

  • 9.1. High-Intensity Focused Ultrasound (HIFU)
  • 9.2. Laser Interstitial Thermal Therapy (LITT)

10. MRI Guided Neurosurgical Ablation Market, by Application

  • 10.1. Brain Tumors
    • 10.1.1. Glioblastoma
    • 10.1.2. Meningioma
    • 10.1.3. Metastatic Tumors
  • 10.2. Chronic Pain
    • 10.2.1. Sciatica
    • 10.2.2. Trigeminal Neuralgia
  • 10.3. Epilepsy
    • 10.3.1. Focal Epilepsy
    • 10.3.2. Temporal Lobe Epilepsy
  • 10.4. Movement Disorders
    • 10.4.1. Dystonia
    • 10.4.2. Essential Tremor
    • 10.4.3. Parkinson's Disease

11. MRI Guided Neurosurgical Ablation Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. MRI Guided Neurosurgical Ablation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. MRI Guided Neurosurgical Ablation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. MRI Guided Neurosurgical Ablation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Monteris Medical Corporation
    • 15.3.3. INSIGHTEC Ltd
    • 15.3.4. ClearPoint Neuro, Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. SternMed GmbH
    • 15.3.7. Cook Group Incorporated
    • 15.3.8. HCA International Limited
    • 15.3.9. Ginger Healthcare Private Ltd.
    • 15.3.10. Brown Neurosurgery

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MRI GUIDED NEUROSURGICAL ABLATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MRI GUIDED NEUROSURGICAL ABLATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRI GUIDED NEUROSURGICAL ABLATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AP